The results showed that the suppression of intestinal FXR eliminated the beneficial effects of the VSG gut microbiota on hepatic steatosis and glucose homeostasis, highlighting that the intestinal FXR-FGF19 pathway may play an important role in the metabolic improvements associated with the transfer of the VSG microbiota. The gene discussed is NR1H4; the disease is Hepatic steatosis.